These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 17478172)

  • 1. Ovarian suppression with a gonadotropin-releasing hormone agonist does not alter insulin-stimulated glucose disposal.
    Cooper BC; Sites CK; Casson PR; Toth MJ
    Fertil Steril; 2007 May; 87(5):1131-8. PubMed ID: 17478172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of ovarian suppression with gonadotropin-releasing hormone agonist on glucose disposal and insulin secretion.
    Toth MJ; Cooper BC; Pratley RE; Mari A; Matthews DE; Casson PR
    Am J Physiol Endocrinol Metab; 2008 Jun; 294(6):E1035-45. PubMed ID: 18413671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence against a role for ovarian hormones in the regulation of blood flow.
    Cooper BC; Sites CK; Fairhurst PA; Toth MJ
    Fertil Steril; 2006 Aug; 86(2):440-7. PubMed ID: 16764868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian suppression with gonadotropin-releasing hormone agonist reduces whole body protein turnover in women.
    Toth MJ; Sites CK; Matthews DE; Casson PR
    Am J Physiol Endocrinol Metab; 2006 Sep; 291(3):E483-90. PubMed ID: 16621894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of depot GnRH agonist on AMH levels in healthy reproductive-aged women.
    Su HI; Maas K; Sluss PM; Chang RJ; Hall JE; Joffe H
    J Clin Endocrinol Metab; 2013 Dec; 98(12):E1961-6. PubMed ID: 24081742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucose metabolism during the menstrual cycle. Assessment with the euglycemic, hyperinsulinemic clamp.
    Diamond MP; Jacob R; Connolly-Diamond M; DeFronzo RA
    J Reprod Med; 1993 Jun; 38(6):417-21. PubMed ID: 8331618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of menopausal status on insulin-stimulated glucose disposal: comparison of middle-aged premenopausal and early postmenopausal women.
    Toth MJ; Sites CK; Eltabbakh GH; Poehlman ET
    Diabetes Care; 2000 Jun; 23(6):801-6. PubMed ID: 10841000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing.
    Ibañez L; Hall JE; Potau N; Carrascosa A; Prat N; Taylor AE
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4103-7. PubMed ID: 8923867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of gonadotropin-releasing hormone hypogonadism on insulin action as assessed by hyperglycemic clamp studies in men.
    Chauhan S; Collins K; Kruger M; Diamond MP
    Fertil Steril; 2004 Apr; 81(4):1092-8. PubMed ID: 15066469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of ovarian and metabolic effects of GnRH modulators in two rat models of polycystic ovary syndrome.
    Patel R; Shah G
    Mol Reprod Dev; 2018 Oct; 85(10):778-789. PubMed ID: 30203897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.
    Moghetti P; Castello R; Negri C; Tosi F; Perrone F; Caputo M; Zanolin E; Muggeo M
    J Clin Endocrinol Metab; 2000 Jan; 85(1):139-46. PubMed ID: 10634377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression and flare regimens of gonadotropin-releasing hormone agonist. Use in women with different basal gonadotropin values in an in vitro fertilization program.
    Toth TL; Awwad JT; Veeck LL; Jones HW; Muasher SJ
    J Reprod Med; 1996 May; 41(5):321-6. PubMed ID: 8725756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Midcycle administration of single-dose GnRHa for luteal phase failure in women with ovarian hyperstimulation. A report of five cases.
    Wu TC
    J Reprod Med; 2000 Feb; 45(2):156-8. PubMed ID: 10710751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma adiponectin level is associated with insulin-stimulated nonoxidative glucose disposal.
    Yokoyama H; Emoto M; Mori K; Araki T; Teramura M; Koyama H; Shoji T; Inaba M; Nishizawa Y
    J Clin Endocrinol Metab; 2006 Jan; 91(1):290-4. PubMed ID: 16234307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Normal ovulatory women with polycystic ovaries have hyperandrogenic pituitary-ovarian responses to gonadotropin-releasing hormone-agonist testing.
    Chang PL; Lindheim SR; Lowre C; Ferin M; Gonzalez F; Berglund L; Carmina E; Sauer MV; Lobo RA
    J Clin Endocrinol Metab; 2000 Mar; 85(3):995-1000. PubMed ID: 10720029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total body fat content and fat topography are associated differently with in vivo glucose metabolism in nonobese and obese nondiabetic women.
    Bonora E; Del Prato S; Bonadonna RC; Gulli G; Solini A; Shank ML; Ghiatas AA; Lancaster JL; Kilcoyne RF; Alyassin AM
    Diabetes; 1992 Sep; 41(9):1151-9. PubMed ID: 1499866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GnRH agonist leuprolide acetate does not confer any protection against ovarian damage induced by chemotherapy and radiation in vitro.
    Bildik G; Akin N; Senbabaoglu F; Sahin GN; Karahuseyinoglu S; Ince U; Taskiran C; Selek U; Yakin K; Guzel Y; Ayhan C; Alper E; Cetiner M; Balaban B; Mandel NM; Esen T; Iwase A; Urman B; Oktem O
    Hum Reprod; 2015 Dec; 30(12):2912-25. PubMed ID: 26466909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of gonadotropin-releasing-hormone-induced hypogonadism on insulin action as assessed by euglycemic clamp studies in men.
    Chauhan S; Diamond MP
    Fertil Steril; 2005 Jul; 84(1):186-90. PubMed ID: 16009176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of insulin-stimulated glucose disposal in middle-aged, premenopausal women.
    Toth MJ; Sites CK; Cefalu WT; Matthews DE; Poehlman ET
    Am J Physiol Endocrinol Metab; 2001 Jul; 281(1):E113-21. PubMed ID: 11404228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Menopause-related differences in inflammation markers and their relationship to body fat distribution and insulin-stimulated glucose disposal.
    Sites CK; Toth MJ; Cushman M; L'Hommedieu GD; Tchernof A; Tracy RP; Poehlman ET
    Fertil Steril; 2002 Jan; 77(1):128-35. PubMed ID: 11779602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.